

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-165. (canceled)

166. (previously presented) An isolated peptide selected from the group consisting of:

CTCGSSDLY (SEQ ID NO:3591);

KTSERSQPR (SEQ ID NO:3579);

QLFTFSPRR (SEQ ID NO:3581);

RMVVGVEHR (SEQ ID NO:3582);

LIFCHSKKK (SEQ ID NO:3583);

GVAGALVAFK (SEQ ID NO:3584); and

TLGFGAYMSK (SEQ ID NO:3586).

167. (canceled)

168. (previously presented) The peptide of claim 166, which is 10 amino acids in length.

169. (canceled)

170. (previously presented) A CTL/HTL epitope conjugate, wherein the CTL epitope of said CTL/HTL epitope conjugate consists of the isolated peptide of claim 166;

wherein said CTL epitope is linked to a non- HCV (Hepatitis C Virus) HTL epitope;

wherein said CTL epitope is linked to said non- HCV HTL epitope either directly or via a spacer at the amino or carboxy terminus of the CTL peptide;

and wherein said spacer is no more than six residues in length.

171-176. (canceled)

177. (previously presented) A composition comprising the peptide of claim 166 and a carrier.

178-246. (canceled)

247. (previously presented) A composition comprising the conjugate of claim 170 and a carrier.

248. (new) An isolated peptide GVAGALVAFK (SEQ ID NO:3584).

249. (new) The peptide of claim 248, which is 10 amino acids in length.

250. (new) A CTL/HTL epitope conjugate, wherein the CTL epitope of said CTL/HTL epitope conjugate consists of the isolated peptide of claim 248;

wherein said CTL epitope is linked to a non- HCV (Hepatitis C Virus) HTL epitope;

wherein said CTL epitope is linked to said non- HCV HTL epitope either directly or via a spacer at the amino or carboxy terminus of the CTL peptide;

and wherein said spacer is no more than six residues in length.

251. (new) A composition comprising the peptide of claim 248 and a carrier.

252. (new) A composition comprising the conjugate of claim 250 and a carrier.